Latest fiscal year 2022 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2022, Solid Biosciences Inc. reported revenue of $8M, down 40.6% year over year. Operating margin was -1315.2% and net margin -1062.3%, on a free-cash-flow margin of -1247.7% with capital expenditure at 37.2% of revenue. Every figure is computed directly from SLDB's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2022 | $8M | -1315.2% | -1062.3% |
| FY2021 | $14M | -530.5% | -530.0% |
| FY2020 | $0M | n/a | n/a |
How does SLDB compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.